A high proportion of cancers have low activity of the enzyme catalase, which degrades the oxidant chemical hydrogen peroxide. This adaptation may be beneficial to the cancer; although oxidant chemicals can be toxic to cells, moderate increases in oxidant stress aid the growth and survival of many cancers. However, low catalase makes cancers potentially vulnerable to attack with hydrogen peroxide. Recently, researchers at the National Institutes of Health have discovered that high concentrations of vitamin C (ascorbate) can react spontaneously with molecular oxygen within tumors to generate large amounts of hydrogen peroxide, which can be lethal to tumor cells whose catalase activity is low. Such large concentrations can only be achieved by high dose intravenous infusions of vitamin C - oral administration is ineffective in this regard. These findings rationalize several previous case reports of objective tumor regression in cancer patients treated repeatedly with high-dose intravenous vitamin C. The vitamin C is not toxic to normal healthy tissues, because they have ample amounts of catalase activity.

However, this strategy can only work well in tumors that have adequate levels of oxygen, as Vitamin C Therapy (ascorbate) reacts with oxygen to produce the hydrogen peroxide. Portions of many tumors tend to be low in oxygen (hypoxic), as the blood flow through tumors is often sluggish compared to that which supplies normal tissues; this evidently could compromise the anti-tumor efficacy of vitamin C Therapy (ascorbate). To overcome this problem, Oasis Hospital employs several complementary techniques that can boost the oxygen content of tumors. Ozone autohemotherapy alters the properties of blood so that it is less viscous, its cellular elements are more flexible, and its oxygenated red blood cells surrender oxygen to tissues more readily (rightward shift of dissociation curve); also, it promotes vasodilation by stimulating nitric oxide release by the endothelial lining of small arteries. The net result is more oxygen delivery to the tumor. This strategy involves drawing a small amount of blood, treating it with a mixture of ozone and oxygen, and re-infusing it. Ozone autohemotherapy has been used extensively in Europe, and is known to be safe.

Oasis also has a novel perfluorochemical known as Perftec that is an oxygen carrier; when infused into a patient, it greatly boosts the total oxygen carrying capacity of blood. After Perftec infusion, patients are asked to breathe air that is enriched in oxygen content, so that the circulating Perftec is loaded with optimal amounts of oxygen. The combination of ozone autohemotherapy and Perftec infusion can be expected to improve oxygen availability in hypoxic regions of tumors - which in turn should boost the ability of intravenous Vitamin C Therapy (ascorbate) to generate hydrogen peroxide in tumors

Share This